PETROSCRAP.COM

Silence Therapeutics – PF-04523655 Phase 2 Study Results Silence Therapeutics – PF-04523655 Phase 2 Study Results Read more on AFX CNF Finance Regulatory News via Yahoo! UK & Ireland…. Click Here to Read More

PsiOxus Therapeutics Initiates Phase II Clinical Study of Wasting Disease Therapeutic MT-102 LONDON–(BUSINESS WIRE)–PsiOxus Therapeutics, Ltd. (PsiOxus) announced initiation of a Phase II study of MT-102, a small molecule therapeutic for the treatment of cancer- and age-related wasting. MT-102 is being developed to reverse the effects of cachexia, a wasting disease that accompanies cancer, heart failure, COPD, renal failure, cirrhosis and rheumatoid arthritis, and that is associated … Read more on Business…. Click Here to Read More

Intarcia Therapeutics Executive Chairman, Kurt Graves to Present at Lazard Capital Markets 7th Annual Healthcare … Intarcia Therapeutics. Inc today announced that Kurt Graves, Executive Chairman of Intarcia Therapeutics, will be presenting at the Lazard Capital Markets 7th Annual Healthcare Conference. Read more on PR Newswire via Yahoo!…. Click Here to Read More

Silence Therapeutics’ Lead RNA Interference Therapeutic Prevents Spread of Cancer to Lungs LONDON, Nov. 10, 2010 /PRNewswire/ — Silence Therapeutics plc (AIM: SLN) (“Silence” or the “Company”) announces positive research findings demonstrating the ability of the Company’s lead RNA interference (RNAi) drug candidate, Atu027, to prevent the formation of pulmonary metastasis in various animal models of cancer metastasis. Researchers showed that Atu027 inhibited multiple key biological … Read more on…. Click Here to Read More

Silence Therapeutics Issued New Patents Covering siRNA Sequences for RNA Interference Therapeutics Silence Therapeutics plc announces the issuance of two new patents by the United States Patent and Trademark Office which are broadly directed to double-stranded short interfering RNA sequences against the validated cancer targets epidermal growth factor receptor related protein and vascular endothelial growth factor receptor 1 . Â EGFR-RP and VEGFR1 have been demonstrated to play key roles in … Read more on PR Newswire via Yahoo!…. Click Here to Read More

Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States Silence Therapeutics plc (AIM: SLN) (“Silence” or the “Company”) announces the issuance of United States patent 7,723,316, titled Compositions and Methods of RNAi Therapeutics For Treatment of Cancer and Other Neovascularization Disease, by the United States Patent and Trademark Office (USPTO). The issued patent, which deepens the Company’s diverse portfolio of RNA interference (RNAi … Read more on SYS-CON…. Click Here to Read More

Silence Therapeutics to Present at Upcoming Investor Conferences Silence Therapeutics plc announces that Philip Haworth, Ph.D., chief executive officer, will present corporate updates at two upcoming industry and financial conferences. Â Dr. Haworth’s presentations will focus on Silence Therapeutics’ comprehensive RNA interference therapeutics platform, broad clinical-stage pipeline and multiple ongoing collaborations with leading pharmaceutical companies. Read more on PR Newswire via Yahoo!…. Click Here to Read More

Open house for Tri-Valley’s girls program Feb. 23 Seventh- and eighth-grade girls and their parents are invited to the seventh annual Reflections on Your Future event. The event is an introduction to a program designed to encourage girls to pursue interests in technology, science, math and engineering. Read more on Contra Costa Times ISA Technovation Awards 2010 announced BANGALORE, INDIA: At a gala award night here, India Semiconductor Association, the semiconductor-driven industry body of the country, on Monday announced Technovation Awards for the year 2010. Read more on CIOL EPO to grant patent notice to BioMimetic Therapeutics BioMimetic Therapeutics, Inc. announced…. Click Here to Read More